Quantcast
Study Finds Many Patients Excluded From Clinical Trials Due

Study Finds Many Patients Excluded From Clinical Trials Due To Prior Cancer

UT Southwestern Medical Center Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center. Among more than 50...

Latest Cancer treatments Stories

2014-09-30 08:30:56

Completion of Enrollment Expected in 2015; Progression-Free Survival Data Expected in mid-2016 LOS ANGELES, Sept. 30, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy....

2014-09-29 12:30:45

BOGOTA, Colombia, Sept. 29, 2014 /PRNewswire/ -- Cancer Treatment Institute of Colombia has announced a promising new drug treatment: a carefully formulated, first-of-its-kind combination of salinomycin and 3-bromopyruvate (3-BrPA) that has already proven successful at treating multiple types of cancer. The team of medical researchers behind this novel treatment are optimistic that it could significantly improve outcomes for many patients who have exhausted current therapeutic...

2014-09-26 23:00:20

Treatment designed to reduce pain and inflammation associated with radiation therapy to the lower bowel. Claremont, CA (PRWEB) September 27, 2014 Synedgen announced today the award of a competitive Small Business Innovation Research (SBIR) Phase I contract from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to demonstrate proof-of-concept activity of Synedgen’s proprietary treatment for radiation proctitis, a condition that causes painful tissue damage to...

2014-09-24 12:29:29

St. Jude Children's Research Hospital study shows that adjusting treatment based on early response to chemotherapy boosts survival of young patients with Philadelphia chromosome-like acute lymphoblastic leukemia MEMPHIS, Tenn., Sept. 24, 2014 /PRNewswire-USNewswire/ -- St. Jude Children's Research Hospital investigators found that adjusting treatment based on early response to chemotherapy made a life-saving difference to young patients with an acute lymphoblastic leukemia (ALL)...

2014-09-22 04:21:55

LUGANO, Switzerland, September 22, 2014 /PRNewswire/ -- Helsinn Group, a company focused on building quality cancer care, today announces that it is supporting an independent educational satellite symposium on Delivering Chemotherapy With Confidence: New Strategies to Minimize Treatment-Induced Nausea and Vomiting at the 38th European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, in 2014. Helsinn has awarded a grant to prIME oncology, a global...

chokeberries
2014-09-20 07:08:16

Becky Attwood, University of Southampton A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals research published online in the Journal of Clinical Pathology. The study by researchers at King’s College Hospital and the University of Southampton suggests that adding nutraceuticals to chemotherapy cycles may improve the effectiveness of conventional drugs, particularly in hard to treat cancers, such...

2014-09-18 08:28:26

- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany, and RIDGEFIELD, Conn., Sept. 18, 2014 /PRNewswire/ -- Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, today jointly announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel...

2014-09-17 20:22:13

Oral presentation at American Society for Radiation Oncology Annual Meeting describes Decipher's ability to identify high-risk prostate cancer patients that may benefit from radiation therapy after surgery, improving treatment decision-making SAN FRANCISCO, Sept. 17, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that data featured in an oral presentation at the 56(th) Annual Meeting of the American Society for Radiation Oncology (ASTRO) demonstrates convincing evidence of the...

2014-09-15 20:22:10

Data presented at American Society for Radiology (ASTRO) Annual Meeting in San Francisco SAN FRANCISCO, Sept. 15, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced data from two new studies presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting demonstrate the ability of its Decipher® Prostate Cancer Classifier, a genomic test capable of predicting aggressiveness of prostate cancer, to influence treatment decisions and improve patient outcomes for...

2014-09-15 16:28:12

Multidisciplinary team composed of six organizations awarded $20,000 for groundbreaking work in mesothelioma and non-small cell lung cancer SYDNEY, Sept. 15, 2014 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that, together with the Asbestos Disease Research Institute (ADRI), it has received the 2014 Cancer Institute New...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related